GYRE
NASDAQ · Biotechnology
Gyre Therapeutics Inc
$4.56
-1.86 (-28.94%)
Open$6.27
Previous Close$6.41
Day High$6.30
Day Low$4.52
52W High$9.14
52W Low$3.97
Volume—
Avg Volume222.7K
Market Cap487.76M
P/E Ratio—
EPS$-0.18
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+556.9% upside
Current
$4.56
$4.56
Target
$29.92
$29.92
$20.05
$29.92 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 120.99M | 231.94M | 230.03M |
| Net Income | 5.21M | -34,891,358 | -29,454,556 |
| Profit Margin | 4.3% | -15.0% | -12.8% |
| EBITDA | 14.50M | -32,635,653 | -32,852,234 |
| Free Cash Flow | — | -26,269,864 | -27,800,469 |
| Rev Growth | +428.5% | -3.5% | +14.1% |
| Debt/Equity | — | 0.25 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |